Swiss healthcare technology company SOPHiA GENETICS has unveiled its new Residual Acute Myeloid (RAM) Application, which expands its comprehensive oncology portfolio.

The new offering will support measurable residual disease (MRD) capabilities and will be available to customers worldwide this summer.

Acute Myeloid Leukemia (AML) is one of the most common forms of leukaemia in adults and is associated with more than 50% relapse within three years after achieving complete remission.

It is necessary to monitor AML patients after treatment, particularly within the first two years, to quickly detect any signs of relapse.

According to the company, MRD testing helps identify early relapse and serves as a primary endpoint in clinical trials to help researchers detect even the smallest trace of cancer.

Next-generation sequencing (NGS)–based MRD testing is the most advanced technique in cancer screening and monitoring and can be found only with highly sensitive methods.

Its SOPHiA DDM RAM Solution will detect a single cancer cell among 10,000 cells, and its analytical capabilities allow users to stay ahead of disease response.

The tool helps detect the sensitive variant down to 0.01% VAF and covers guideline-recommended genes to deliver superior insights for residual acute myeloid.

SOPHiA GENETICS chief medical officer and chief product officer Philippe Menu said: “AML unfortunately remains an area of high unmet medical need today, with associated suboptimal patient outcomes.

“MRD measurement and monitoring has a critical role to play, for example by enabling research into the most optimal sequencing of therapies. We are proud to contribute to the fight against AML through our SOPHiA DDM RAM Solution.

“In particular we feel that the capability to seamlessly track longitudinally the evolution of individual mutations over time through a dedicated add-on module of our SOPHiA DDM Platform has the potential to be a game-changer for clinical researchers.”

SOPHiA said that its DDM RAM Solution will provide access to longitudinal variant monitoring, allowing the users to visualise the mutational landscape for each patient and its evolution.

The solution provides the most up-to-date databases and customisable reporting features to generate graphical representations and comprehensive MRD reports. In addition, the SOPHiA DDM RAM Solution will continually enrich its machine-learning algorithms to provide the most accurate MRD results within four days, said the Swiss company.